141 related articles for article (PubMed ID: 11551492)
1. N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention.
Sharp RM; Bello-DeOcampo D; Quader ST; Webber MM
Mutat Res; 2001 Sep; 496(1-2):163-70. PubMed ID: 11551492
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).
Webber MM; Bello-DeOcampo D; Quader S; Deocampo ND; Metcalfe WS; Sharp RM
Clin Exp Metastasis; 1999 May; 17(3):255-63. PubMed ID: 10432011
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model.
Quader ST; Bello-DeOcampo D; Williams DE; Kleinman HK; Webber MM
Mutat Res; 2001 Sep; 496(1-2):153-61. PubMed ID: 11551491
[TBL] [Abstract][Full Text] [Related]
4. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer.
Tokar EJ; Ancrile BB; Ablin RJ; Webber MM
J Exp Ther Oncol; 2006; 5(4):323-33. PubMed ID: 17024972
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide.
Jinno H; Steiner MG; Mehta RG; Osborne MP; Telang NT
Carcinogenesis; 1999 Feb; 20(2):229-36. PubMed ID: 10069458
[TBL] [Abstract][Full Text] [Related]
6. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.
Panigone S; Debernardi S; Taya Y; Fontanella E; Airoldi R; Delia D
Oncogene; 2000 Aug; 19(35):4035-41. PubMed ID: 10962560
[TBL] [Abstract][Full Text] [Related]
7. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Lewis KC; Hochadel JF
Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
[TBL] [Abstract][Full Text] [Related]
8. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Faderl S; Lotan R; Kantarjian HM; Harris D; Van Q; Estrov Z
Leuk Res; 2003 Mar; 27(3):259-66. PubMed ID: 12537979
[TBL] [Abstract][Full Text] [Related]
9. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
[TBL] [Abstract][Full Text] [Related]
10. The role of alpha 6 beta 1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells.
Bello-DeOcampo D; Kleinman HK; Webber MM
Mutat Res; 2001 Sep; 480-481():209-17. PubMed ID: 11506815
[TBL] [Abstract][Full Text] [Related]
11. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression.
Shaker MR; Yang G; Timme TL; Park SH; Kadmon D; Ren C; Ji X; Lee HM; Sehgal I; Anzano M; Sporn MB; Thompson TC
Clin Exp Metastasis; 2000; 18(5):429-38. PubMed ID: 11467776
[TBL] [Abstract][Full Text] [Related]
12. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
[TBL] [Abstract][Full Text] [Related]
13. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines.
Kazmi SM; Plante RK; Visconti V; Lau CY
Cancer Res; 1996 Mar; 56(5):1056-62. PubMed ID: 8640761
[TBL] [Abstract][Full Text] [Related]
14. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.
Maurer BJ; Metelitsa LS; Seeger RC; Cabot MC; Reynolds CP
J Natl Cancer Inst; 1999 Jul; 91(13):1138-46. PubMed ID: 10393722
[TBL] [Abstract][Full Text] [Related]
15. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis.
Shen JC; Wang TT; Chang S; Hursting SD
Mol Carcinog; 1999 Mar; 24(3):160-8. PubMed ID: 10204800
[TBL] [Abstract][Full Text] [Related]
17. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.
Simeone AM; Colella S; Krahe R; Johnson MM; Mora E; Tari AM
Carcinogenesis; 2006 Mar; 27(3):568-77. PubMed ID: 16199439
[TBL] [Abstract][Full Text] [Related]
18. Stage-specific effect of N-(4-hydroxyphenyl)retinamide on cell growth in squamous cell carcinogenesis.
Kabbout M; Hatoum A; Abou-Lteif G; Chakroun I; Homaidan FR; Darwiche N
Mol Carcinog; 2004 May; 40(1):12-23. PubMed ID: 15108326
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of fenretinide on cell-matrix interactions.
Vaccari M; Silingardi P; Argnani A; Horn W; Giungi M; Mascolo MG; Grilli S; Colacci A
Anticancer Res; 2000; 20(5A):3059-66. PubMed ID: 11062723
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.
Kalemkerian GP; Slusher R; Ramalingam S; Gadgeel S; Mabry M
J Natl Cancer Inst; 1995 Nov; 87(22):1674-80. PubMed ID: 7473815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
